

S-Adenosyl Methionine Cofactor Modifications Enhance the Biocatalytic Repertoire of Small Molecule C-Alkylation

Iain J. W. McKean, Joanna C. Sadler, Anibal Cuetos, Amina Frese, Luke D. Humphreys, Gideon Grogan,* Paul A. Hoskisson,* and Glenn A. Burley*

Abstract: A tandem enzymatic strategy to enhance the scope of C-alkylation of small molecules via the *in situ* formation of S-adenosyl methionine (SAM) cofactor analogues is described. A solvent-exposed channel present in the SAM-forming enzyme *SalL* tolerates 5'-chloro-5'-deoxyadenosine (CIDA) analogues modified at the 2-position of the adenine nucleobase. Coupling *SalL*-catalyzed cofactor production with C-(m)ethyl transfer to coumarin substrates catalyzed by the methyltransferase (MTase) *NovO* forms C-(m)ethylated coumarins in superior yield and greater substrate scope relative to that obtained using cofactors lacking nucleobase modifications. Establishing the molecular determinants that influence C-alkylation provides the basis to develop a late-stage enzymatic platform for the preparation of high value small molecules.

Regiospecific methylation is an essential process used in nature to modulate biological function.^[1,2] From an industrial perspective, methylation of small molecules is a powerful strategy to fine-tune their physicochemical properties and enhance overall drug potency.^[3] In order to fully exploit this “magic methyl effect” across the pharmaceutical and biotechnology sectors,^[4,5] robust methods are required to precisely methylate—and indeed alkylate—substrates in an environmentally benign manner.^[5–7]

Traditional synthetic approaches have typically involved using Friedel–Crafts,^[8] radical-based methods,^[9,10] and more recently, transition-metal catalyzed activation of C(sp²)–H bonds.^[11–13] However, obtaining regiospecificity, particularly when this is required at a late-stage in a synthetic workflow, is

an enduring challenge.^[3] In contrast, MTases catalyze regio-specific C-methylation of biomolecules using the SAM cofactor as the corresponding methyl donor.^[14–17]

The repertoire of C-methylation extends to small molecules, which opens up opportunities to tailor these enzymes as a general platform for biocatalytic C–C bond formation (Figure 1a). A representative example is *NovO*, which catalyzes the C-alkylation of coumarins (e.g., **1**), and forms




Figure 1. Biocatalytic C-alkylation using a) S-alkylated SAM analogues, and b) a tandem enzymatic process. c) Enhancement of yield and substrate scope of C-(m)ethylation by modifications to the cofactor scaffold. Ade = adenine.

[*] I. J. W. McKean, Dr. J. C. Sadler, Prof. G. A. Burley
Department of Pure and Applied Chemistry, University of Strathclyde
298 Cathedral Street, Glasgow, G1 1XL (UK)
E-mail: glenn.burley@strath.ac.uk

I. J. W. McKean, Prof. P. A. Hoskisson
Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde
161 Cathedral Street, Glasgow, G4 0RE (UK)
E-mail: paul.hoskisson@strath.ac.uk

Dr. J. C. Sadler, Dr. L. D. Humphreys
GlaxoSmithKline Medicines Research Centre
Gunnels Wood Road, Stevenage, SG12NY (UK)

Dr. A. Cuetos, Dr. A. Frese, Prof. G. Grogan
Department of Chemistry, University of York
Heslington, York, YO10 5DD (UK)
E-mail: gideon.grogan@york.ac.uk

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/anie.201908681>.

a key step in the biosynthesis of novobiocin.^[18–20] A hallmark of NovO is its substrate promiscuity (e.g., **1**) and the ability to utilize *S*-alkylated analogues of SAM to form products such as **2** (Figure 1a).^[20,21]

One limitation of this process is the need to prepare these cofactors by chemical synthesis, which is laborious, low yielding, and produces both epimers at the sulfur center.^[22–26] Furthermore, SAM analogues are inherently unstable in buffered solution ($t_{1/2}$ 942 min for SAM at pH 8).^[27,28] A more step- and atom-efficient strategy is to couple cofactor formation with *C*-alkyl transfer.^[15,29,30] One example of this one-pot process is the generation of cofactor analogues *in situ* from either CIDA or ATP and (m)ethionine,^[15,29–33] followed by *C*-(m)ethyl transfer catalyzed by a MTase (Figure 1b).^[34] CIDA is a shelf-stable, atom-economical adenosine source for such a process catalyzed by SalL compared to ATP, which is a substrate for SAM production by methionine adenosyltransferase (MAT).^[15,27,29,35,36]

Although in-depth knowledge of the substrate promiscuity of *C*-MTases has been garnered from structural and mutagenesis studies,^[17,19,20,37] little is known about how the structural features of the SAM cofactor itself influences the yield and scope of *C*-alkylation.^[14,30] Herein, we showcase a method to address these limitations by strategic modifications to SAM and *S*-adenosyl ethionine (SAE, Figure 1c).

An earlier structural study of SalL in complex with CIDA and methionine revealed a solvent-exposed channel into the active site.^[38–40] To explore this in more detail, we obtained two structures of wild-type SalL with SAM and chloride (6RYZ, 1.50 Å), and with CIDA alone (6RZZ, 1.77 Å; Figure 2, Supporting Information, Table S1). One significant difference in our structures compared to those obtained

previously was a rotation of the sidechain of Arg243, from the solvent-exposed exterior of the protein to the interior of the active site, enabling the formation of electrostatic interactions between Arg243 and the carboxylate of SAM (Figure 2 and Supporting Information, Figure S1), and the side chain of Glu17 from the adjacent monomer. No associated changes in the solvent-exposed channel were observed. These structures were then used as a guide for the preparation of point mutants in order to explore the roles of specific residues in catalysis. Phe186Leu, Trp129Phe, Asp183Glu, Trp190Ala, Val12Met, and Tyr70Met displayed a reduced level of activity relative to wild-type SalL (Supporting Information, Table S2 and Figure S2). The Phe186Leu mutant was able to form SAM and SAM analogues, albeit in slightly poorer conversions relative to the wild-type (Supporting Information, Figure S15). In contrast, enzymatic activity was abolished in the Asp183Ala, Asn188Ala, Phe186Ala, and Phe228Ile/Ala mutants. This suggests that π-stacking between Phe228 and the adenine nucleobase, the electrostatic interaction between the Met carboxylate and Asp183, and H-bonding to the Hoogsteen face of the adenine nucleobase (Asn188) are essential for catalysis.

Further supporting evidence for the importance of Asp183 for catalysis was observed when a tetrazole carboxylic acid bioisostere of methionine was used (Figure 3a). The use of *tert*Met^[27] resulted in 99 % conversion to **4c**, despite slower reaction kinetics relative to SAM formation (**4a**, Figure 3b and Supporting Information, Table S3 and Figures S8–12, S14). However, an increase in steric bulk at the sulfur center i.e., by replacing Met with L-ethionine formed SAE (**4b**) albeit in lower conversion (41 %) relative to SAM.

Replacing adenine with 7-deazaadenine (**4d**) resulted in only 10 % conversion (Figure 3c),^[27] whereas a hypoxanthine nucleobase did not form **4e**. This suggests that the interaction between the N7 of adenine and Asn188 is critical for the catalytic function of SalL. High conversions to **4f–j** were observed using analogues containing modifications to the 2- and 6-position of adenine. Combining 2,6-diamino or 2-chloro-6-aminoadenine modifications with *tert*Met produced **4k** and **4l** in greater than 99 % and 41 % conversion, respectively (Figure 3d). Although no formation of **4m** was observed when *tert*ethionine was used, SAE analogues **4n** and **4o** were formed in 78 % and 37 %, respectively. Finally, no cofactor products were formed using CIDA substrates lacking either 2'/3' ribose hydroxyl groups (**4p–r**).

Inspection of the crystal structure of NovO in complex with *S*-adenosylhomocysteine (SAH) revealed the presence of a hydrophobic cleft with a volume of approximately 21 Å³.^[18] This is in the exact location of the 2-position of the adenine nucleobase (Figure 4 and Supporting Information, Figure S3). We surmised that SAM/SAE cofactors bearing modifications of complementary steric volume at this position would also be substrates for NovO. Our tandem enzymatic process using purified SalL and NovO in the presence of stoichiometric amounts of CIDA analogue, L-Met, and coumarin (**5**) indeed demonstrated the enhanced conversion of methylated coumarin (**5a**) via the *in situ* formation of modified SAM analogues relative to SAM (Supporting Information, Figure S70 and Table S5).




Figure 2. Wild-type SalL in complex with CIDA and L-Met (PDB 2Q61^[31]) superimposed with wild-type SalL in complex with SAM (6RYZ, this study). Neighboring monomers and amino acid side-chains of 2Q61 are shown in cyan and light blue. Arg243 and SAM (6RYZ, coral) illustrate relocation of this side chain to form new ionic interactions (coral) with the SAM carboxylate and the side chain of Glu17.




Figure 3. a) Formation of SAM/SAE analogues catalyzed by Sall. b) Reaction kinetics and % conversions using modified Met analogues. Substrate scope of cofactor synthesis incorporating c) nucleobase and d) a combination of nucleobase and amino acid modifications. Assay conditions: CIDA/CIDA analogue (400 μ M), L-Met/L-Ethionine (2.00 mM), Sall (2.10 μ M), DTT (1.00 mM) and BSA (1.00 mg mL⁻¹), potassium phosphate buffer (100 mM, pH 6.8), 24 h, 37°C. % conversions determined by RP-HPLC using a ratio of the peak area (254 nm) of the CIDA analogue to SAM/SAE analogue and 5'-methylthioadenosine (or analogue).^[27]

For example, using analogues **4h** or **4j** formed in situ, enhanced the conversion to **5a** from 17% (using SAM) to 53% (**4h**) and 39% (**4j**). Further enhancement was achieved using an excess of CIDA analogues (2 equiv) and L-Met (10 equiv). In this instance, the conversion of **5** to **5a** improved to 85% (**4h**) and 77% (**4j**) relative to 49% when

SAM was generated in situ (Figure 5). As identified in an earlier study, MTAN was added to the reaction mixture in order to degrade the SAH analogue, which inhibits NovO.^[34] The 2-modified alkyne cofactor **4i** displayed comparable conversion (**5a**, 50%) to SAM, whereas the formation of the 2-amino-6-chloro analogue (**4g**) in situ did not form **5a**.




Figure 4. Crystal structure of NovO in complex with SAH highlighting the 2-position of adenine projecting towards a hydrophobic cleft (red. PDB: 5MGZ).




Figure 5. C-(m)ethylation of 5 catalyzed by NovO using modified cofactors.

Tetrazole analogues **4c**, **4k**, and **4l** produced significantly lower amounts of **5a** relative to SAM. Enhanced levels of *C*-ethylation of **5** were also observed, producing **5b** from **4n** (39%) and **4o** (25%) relative to only 24% when SAE was used. Exploration of the wider scope of methylating (**5a–13a**) and ethylating (**5b–13b**) a suite of 3-substituted coumarins (**5–13**) exemplified the superiority of using nucleobase-modified SAM/SAE analogues (Figure 6).^[34] In almost all examples, the 2-amino- and 2-chloro-modified cofactors outperformed SAM in methylating **5–13**. One exception was triazole **11**, in which no *C*-(m)ethylation was observed using any of the cofactors tested.

Finally, the ability of our tandem enzymatic process to (m)ethylate coumarin scaffolds with known biological activity and clinical relevance was explored. The core of coumarin **12a** is a precursor to a known inhibitor of Hsp90,^[41] and is being pursued as an anti-cancer therapy,^[42] whilst **13a** is a metabolite of warfarin.^[43] *C*-methylation was almost quantitative, producing **12a** (95% conversion; 23% isolated yield) and **13a** (92%) when **4j** was used compared to only 15% (**12a**) and 7% (**13a**) conversion using SAM. Ethylation of both substrates produced **12b** and **13b** in 21% and 37%, respectively. In contrast, **12b** was formed in only trace amounts (3%), whereas no ethylated product (**13b**) was formed using SAE.

In summary, we have established a new biocatalytic strategy that enhances the yield and substrate scope of small molecule *C*-(m)ethylation by incorporating nucleobase modifications within the SAM cofactor. Key to the success of this approach is the compatibility of SalL and NovO to couple *in situ* generation of SAM/SAE cofactor analogues (SalL) with *C*-(m)ethyl transfer (NovO). We envisage that blending directed evolution strategies with cofactor analogue mapping, and new strategies to recycle the SAH product formed by *C*-alkylation^[15,44] will provide new opportunities to identify enzyme variants with wider substrate promiscuity.

Acknowledgements

I.J.W.M and G.A.B. thank the Biotechnology and Biological Sciences Research Council (BBSRC) for funding (BB/M016366/1; BB/N016378/1). J.C.S. thanks GlaxoSmithKline (GSK) and the University of Strathclyde for an industrial PhD studentship. A.C. was funded by the BBSRC (BB/P005578/1). A.F. was funded by a studentship from GSK. We thank Dr. Johan Turkenburg and Mr. Sam Hart for assistance with X-ray data collection and the Diamond Light Source for access to beamlines (mx-9948). Finally, we thank Dr. Allan J.B. Watson for his suggestion to explore warfarin as a NovO substrate.




Figure 6. Substrate scope of C-(m)ethylation of coumarins 6–13. CIDA/CIDA analogue (400 µM), L-Met/L-ethionine (2.00 mM), coumarin (200 µM), Sall (2.10 µM), DTT (1.00 mM) and BSA (1 mg mL⁻¹), potassium phosphate buffer (100 mM, pH 6.8), 24 h, 37°C then NovO (9.38 µM) and MTAN (132 nM).^[18,34]*Optimized conditions for 13a/13b with 4j/4a: 2-Cl-CIDA 1.6 mM, L-Met/L-ethionine (8.00 mM), 7-hydroxywarfarin (200 µM), Sall (4.20 µM), DTT (4.00 mM) and BSA (1 mg mL⁻¹), potassium phosphate buffer (100 mM, pH 6.8) 24 h, 37°C then NovO (42.6 µM) and MTAN (528 nM)% conversions were determined by RP-HPLC using a ratio of the peak area at 300 nm of the coumarin starting material to the product.^[18,34]

Conflict of interest

The authors declare no conflict of interest.

How to cite: *Angew. Chem. Int. Ed.* **2019**, *58*, 17583–17588
Angew. Chem. **2019**, *131*, 17747–17752

Keywords: alkylation · biocatalysis · coumarin · methyltransferase · S-adenosylmethionine

[1] L. D. Moore, T. Le, G. Fan, *Neuropharmacology* **2013**, *38*, 23.

- [2] E. M. Harcourt, A. M. Kietrys, E. T. Kool, *Nature* **2017**, *541*, 339.
- [3] T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, *Chem. Soc. Rev.* **2016**, *45*, 546–576.
- [4] A.-W. Struck, M. L. Thompson, L. S. Wong, J. Micklefield, *ChemBioChem* **2012**, *13*, 2642–2655.
- [5] H. Schönherr, T. Cernak, *Angew. Chem. Int. Ed.* **2013**, *52*, 12256–12267; *Angew. Chem.* **2013**, *125*, 12480–12492.
- [6] Y. Chen, *Chem. Eur. J.* **2019**, *25*, 3405–3439.
- [7] J. Boström, D. G. Brown, R. J. Young, G. M. Keserü, *Nat. Rev. Drug Discovery* **2018**, *17*, 709.
- [8] M. Rueping, B. J. Nachtsheim, *Beilstein J. Org. Chem.* **2010**, *6*, 6.
- [9] J. Gui, Q. Zhou, C.-M. Pan, Y. Yabe, A. C. Burns, M. R. Collins, M. A. Ornelas, Y. Ishihara, P. S. Baran, *J. Am. Chem. Soc.* **2014**, *136*, 4853–4856.
- [10] Q. Huang, S. Z. Zard, *Org. Lett.* **2018**, *20*, 1413–1416.
- [11] X. Chen, K. M. Engle, D.-H. Wang, J.-Q. Yu, *Angew. Chem. Int. Ed.* **2009**, *48*, 5094–5115; *Angew. Chem.* **2009**, *121*, 5196–5217.
- [12] J. Li, K. Korvorapun, S. De Sarkar, T. Rogge, D. J. Burns, S. Warratz, L. Ackermann, *Nat. Commun.* **2017**, *8*, 15430.
- [13] G. Yan, A. J. Borah, L. Wang, M. Yang, *Adv. Synth. Catal.* **2015**, *357*, 1333–1350.
- [14] M. R. Bennett, S. A. Shepherd, V. A. Cronin, J. Micklefield, *Curr. Opin. Chem. Biol.* **2017**, *37*, 97–106.
- [15] S. Mordhorst, J. Siegrist, M. Müller, M. Richter, J. N. Andexer, *Angew. Chem. Int. Ed.* **2017**, *56*, 4037–4041; *Angew. Chem.* **2017**, *129*, 4095–4099.
- [16] M. Tomukviene, M. Mickuté, G. Vilkaite, S. Klimašauskas, *Curr. Opin. Biotechnol.* **2019**, *55*, 114–123.
- [17] T. Pavkov-Keller, K. Steiner, M. Faber, M. Tengg, H. Schwab, M. Gruber-Khadjawi, K. Gruber, *PLoS One* **2017**, *12*, e0171056.
- [18] J. C. Sadler, C.-w. H. Chung, J. E. Mosley, G. A. Burley, L. D. Humphreys, *ACS Chem. Biol.* **2017**, *12*, 374–379.
- [19] M. Pacholec, J. Tao, C. T. Walsh, *Biochemistry* **2005**, *44*, 14969–14976.
- [20] H. Stecher, M. Tengg, B. J. Ueberbacher, P. Remler, H. Schwab, H. Griengl, M. Gruber-Khadjawi, *Angew. Chem. Int. Ed.* **2009**, *48*, 9546–9548; *Angew. Chem.* **2009**, *121*, 9710–9712.
- [21] M. Tengg, H. Stecher, L. Offner, K. Plasch, F. Anderl, H. Weber, H. Schwab, M. Gruber-Khadjawi, *ChemCatChem* **2016**, *8*, 1354–1360.
- [22] G. Lukinavičius, V. Lapienė, Z. Staševskij, C. Dalhoff, E. Weinhold, S. Klimašauskas, *J. Am. Chem. Soc.* **2007**, *129*, 2758–2759.
- [23] J. Zhang, Y. G. Zheng, *ACS Chem. Biol.* **2016**, *11*, 583–597.
- [24] K. Islam, Y. Chen, H. Wu, I. R. Bothwell, G. J. Blum, H. Zeng, A. Dong, W. Zheng, J. Min, H. Deng, M. Luo, *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 16778–16783.
- [25] W. Peters, S. Willnow, M. Duisken, H. Kleine, T. Macherey, K. E. Duncan, D. W. Litchfield, B. Lüscher, E. Weinhold, *Angew. Chem. Int. Ed.* **2010**, *49*, 5170–5173; *Angew. Chem.* **2010**, *122*, 5296–5299.
- [26] C. Dalhoff, G. Lukinavičius, S. Klimašauskas, E. Weinhold, *Nat. Chem. Biol.* **2005**, *2*, 31.
- [27] T. D. Huber, F. Wang, S. Singh, B. R. Johnson, J. Zhang, M. Sunkara, S. G. Van Lanen, A. J. Morris, G. N. Phillips, J. S. Thorson, *ACS Chem. Biol.* **2016**, *11*, 2484–2491.
- [28] T. D. Huber, B. R. Johnson, J. Zhang, J. S. Thorson, *Curr. Opin. Biotechnol.* **2016**, *42*, 189–197.
- [29] J. M. Lipson, M. Thomsen, B. S. Moore, R. P. Clausen, J. J. La Clair, M. D. Burkart, *ChemBioChem* **2013**, *14*, 950–953.
- [30] C. Vranken, A. Fin, P. Tufar, J. Hofkens, M. D. Burkart, Y. Tor, *Org. Biomol. Chem.* **2016**, *14*, 6189–6192.
- [31] A. S. Eustáquio, F. Pojer, J. P. Noel, B. S. Moore, *Nat. Chem. Biol.* **2007**, *4*, 69.
- [32] F. Muttach, A. Rentmeister, *Angew. Chem. Int. Ed.* **2016**, *55*, 1917–1920; *Angew. Chem.* **2016**, *128*, 1951–1954.
- [33] B. J. C. Law, A.-W. Struck, M. R. Bennett, B. Wilkinson, J. Micklefield, *Chem. Sci.* **2015**, *6*, 2885–2892.
- [34] J. C. Sadler, L. D. Humphreys, R. Snajdrova, G. A. Burley, *ChemBioChem* **2017**, *18*, 992–995.
- [35] S. Singh, J. Zhang, T. D. Huber, M. Sunkara, K. Hurley, R. D. Goff, G. Wang, W. Zhang, C. Liu, J. Rohr, S. G. Van Lanen, A. J. Morris, J. S. Thorson, *Angew. Chem. Int. Ed.* **2014**, *53*, 3965–3969; *Angew. Chem.* **2014**, *126*, 4046–4050.
- [36] B. J. C. Law, M. R. Bennett, M. L. Thompson, C. Levi, S. A. Shepherd, D. Leys, J. Micklefield, *Angew. Chem. Int. Ed.* **2016**, *55*, 2683–2687; *Angew. Chem.* **2016**, *128*, 2733–2737.
- [37] A. Gutmann, M. Schiller, M. Gruber-Khadjawi, B. Nidetzky, *Org. Biomol. Chem.* **2017**, *15*, 7917–7924.
- [38] W. L. Yeo, X. Chew, D. J. Smith, K. P. Chan, H. Sun, H. Zhao, Y. H. Lim, E. L. Ang, *Chem. Commun.* **2017**, *53*, 2559–2562.
- [39] S. Thompson, S. A. McMahon, J. H. Naismith, D. O'Hagan, *Bioorg. Chem.* **2016**, *64*, 37–41.
- [40] S. Thompson, Q. Zhang, M. Onega, S. McMahon, I. Fleming, S. Ashworth, J. H. Naismith, J. Passchier, D. O'Hagan, *Angew. Chem. Int. Ed.* **2014**, *53*, 8913–8918; *Angew. Chem.* **2014**, *126*, 9059–9064.
- [41] X. M. Yu, G. Shen, L. Neckers, H. Blake, J. Holzbeierlein, B. Cronk, B. S. J. Blagg, *J. Am. Chem. Soc.* **2005**, *127*, 12778–12779.
- [42] J. Zhao, H. Zhao, J. A. Hall, D. Brown, E. Brandes, J. Bazzill, P. T. Grogan, C. Subramanian, G. Vielhauer, M. S. Cohen, B. S. J. Blagg, *MedChemComm* **2014**, *5*, 1317–1323.
- [43] A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, W. F. Trager, *Chem. Res. Toxicol.* **1992**, *5*, 54–59.
- [44] C. Liao, F. P. Seebeck, *Nat. Catal.* **2019**, *2*, 696–701.

Manuscript received: July 12, 2019

Revised manuscript received: September 11, 2019

Accepted manuscript online: October 1, 2019

Version of record online: October 21, 2019